[go: up one dir, main page]

MX2019011679A - Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. - Google Patents

Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.

Info

Publication number
MX2019011679A
MX2019011679A MX2019011679A MX2019011679A MX2019011679A MX 2019011679 A MX2019011679 A MX 2019011679A MX 2019011679 A MX2019011679 A MX 2019011679A MX 2019011679 A MX2019011679 A MX 2019011679A MX 2019011679 A MX2019011679 A MX 2019011679A
Authority
MX
Mexico
Prior art keywords
cytotoxic
replacement
cellular immunotherapy
conditioning before
methods
Prior art date
Application number
MX2019011679A
Other languages
English (en)
Inventor
Ann Deisher Theresa
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of MX2019011679A publication Critical patent/MX2019011679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente composiciones terapéuticas novedosas y los métodos que mantienen las inmunoterapias celulares en la circulación o en el sitio de inyección durante períodos de tiempo prolongados sin recurrir al uso de un pre-acondicionamiento citotóxico. Más específicamente las composiciones y métodos en la presente provocan linfodepleción y reducen o extirpan los sitios en los linfáticos secundarios donde se une y se secuestra la inmunoterapia celular, sin el uso de un preacondicionamiento citotóxico.
MX2019011679A 2017-04-01 2018-03-30 Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. MX2019011679A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US201862624454P 2018-01-31 2018-01-31
PCT/US2018/025517 WO2018183927A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Publications (1)

Publication Number Publication Date
MX2019011679A true MX2019011679A (es) 2019-11-01

Family

ID=62111173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011679A MX2019011679A (es) 2017-04-01 2018-03-30 Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.

Country Status (13)

Country Link
US (2) US11219628B2 (es)
EP (1) EP3490605B1 (es)
JP (2) JP6748221B2 (es)
KR (1) KR102509006B1 (es)
CN (1) CN110475571B (es)
AU (1) AU2018243753A1 (es)
BR (1) BR112019020214A2 (es)
CA (1) CA3054443A1 (es)
ES (1) ES2954311T3 (es)
IL (1) IL269209B2 (es)
MX (1) MX2019011679A (es)
SG (1) SG11201907744QA (es)
WO (1) WO2018183927A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
MX2019011679A (es) 2017-04-01 2019-11-01 Avm Biotechnology Llc Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
EP3634528B1 (en) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
JP7410034B2 (ja) 2018-02-01 2024-01-09 シファメド・ホールディングス・エルエルシー 血管内血液ポンプならびに使用および製造の方法
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020028537A1 (en) 2018-07-31 2020-02-06 Shifamed Holdings, Llc Intravascaular blood pumps and methods of use
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EA202191345A1 (ru) 2018-11-14 2021-10-08 Авм Байотекнолоджи, Ллс Стабильный состав глюкокортикоидов
CN113316454A (zh) * 2018-11-16 2021-08-27 拉帕治疗有限公司 用于利用制造的t细胞治疗癌症的方法
WO2020123444A1 (en) * 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
US11964145B2 (en) 2019-07-12 2024-04-23 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof
US12121713B2 (en) 2019-09-25 2024-10-22 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
WO2021062270A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
AU2020380366B2 (en) * 2019-11-06 2025-02-13 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
WO2021168375A1 (en) * 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
JP2023514788A (ja) 2020-02-28 2023-04-10 エーブイエム・バイオテクノロジー・エルエルシー リンパ球集団およびそれを生産するための方法
CN111443210B (zh) * 2020-04-10 2023-09-22 青海大学附属医院 泡型包虫病早期诊疗生物标志物及其应用
WO2021207724A2 (en) * 2020-04-10 2021-10-14 North Carolina State University Enhanced viral transduction of mammalian cells using material scaffolds
JP2023524434A (ja) 2020-04-29 2023-06-12 エーブイエム・バイオテクノロジー・エルエルシー 新規療法
AU2020451285A1 (en) 2020-06-01 2022-12-22 Avm Biotechnology, Llc Methods of treatment using ICAM-modulating agents
CN113797313A (zh) * 2020-06-11 2021-12-17 华北制药集团新药研究开发有限责任公司 卡非佐米作为冠状病毒广谱抑制剂的新用途
WO2022049572A1 (en) * 2020-09-01 2022-03-10 The National Institute for Biotechnology in the Negev Ltd. Immune system restoration by cell therapy
CN113322233A (zh) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 一种改进的基于新生抗原反应性t细胞的制备方法及应用
WO2022226355A2 (en) * 2021-04-23 2022-10-27 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
CN115850387B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 超高亲和力的靶向pd-l1的小蛋白及药物组合物
KR20240055044A (ko) 2021-09-01 2024-04-26 에이브이엠 바이오테크놀로지, 엘엘씨 림프구 집단 및 이를 생산하는 방법
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN116606352B (zh) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE69739210D1 (de) * 1997-12-16 2009-02-26 Univ Zuerich Diagnostik für übertragbare spongiforme Enzephalopathie
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
IL164079A0 (en) 2002-03-15 2005-12-18 Us Dept Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
CN103494817A (zh) 2002-05-17 2014-01-08 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
DK1835924T3 (da) 2004-12-23 2013-11-04 Ethicon Inc Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
WO2006114115A1 (de) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
KR20080039929A (ko) 2005-07-22 2008-05-07 와이스 테라퓨틱스 가부시키가이샤 항-ｃｄ26 항체 및 이들의 사용 방법
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2117543A4 (en) 2007-02-01 2011-09-28 Nephrogen Llc POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY
CA2725198A1 (en) 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
ES2627043T3 (es) 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
BR112013003169B1 (pt) * 2010-08-18 2022-05-24 Theresa Deisher Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103442768A (zh) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 治疗癌的组合物和方法
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
JP7197979B2 (ja) * 2015-05-28 2022-12-28 カイト ファーマ インコーポレイテッド Ｔ細胞療法のために患者をコンディショニングする方法
CA3044261A1 (en) * 2016-11-30 2018-06-07 Intrexon Corporation Steroid administration and immunotherapy
MX2019011679A (es) 2017-04-01 2019-11-01 Avm Biotechnology Llc Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.

Also Published As

Publication number Publication date
CN110475571B (zh) 2023-04-04
US11219628B2 (en) 2022-01-11
WO2018183927A1 (en) 2018-10-04
US20180296572A1 (en) 2018-10-18
JP6748221B2 (ja) 2020-08-26
JP7162632B2 (ja) 2022-10-28
JP2020114837A (ja) 2020-07-30
US20220160729A1 (en) 2022-05-26
SG11201907744QA (en) 2019-09-27
CA3054443A1 (en) 2018-10-14
KR20190130624A (ko) 2019-11-22
KR102509006B1 (ko) 2023-03-13
EP3490605B1 (en) 2023-06-07
BR112019020214A2 (pt) 2020-04-22
IL269209B1 (en) 2023-07-01
ES2954311T3 (es) 2023-11-21
IL269209A (en) 2019-11-28
EP3490605A1 (en) 2019-06-05
EP3490605C0 (en) 2023-06-07
IL269209B2 (en) 2023-11-01
AU2018243753A1 (en) 2019-10-10
CN110475571A (zh) 2019-11-19
JP2019515888A (ja) 2019-06-13

Similar Documents

Publication Publication Date Title
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
CO2020003714A2 (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos
CL2022001671A1 (es) Inhibidores de sos1
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
PE20210163A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
DOP2017000015A (es) Compuestos de heteroarilo y sus usos
CR20200544A (es) Inhibidores de mcl-1
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CY1124913T1 (el) Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
TWD195240S (zh) 輔助燈
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2020016151A2 (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos